Molecular Partners Announces Annual General Meeting 2025
Molecular Partners AG, a pioneering biotech company based in Switzerland, has shared details about its upcoming Annual General Meeting (AGM) scheduled for this year. This significant event is part of the company's commitment to transparency and engaging with its stakeholders.
Details of the Annual General Meeting
The Annual General Meeting will take place at 9:00 AM CET, with doors opening at 8:30 AM. The venue for this gathering will be JED Events located on Zürcherstrasse in Schlieren, Switzerland. Attendees can expect an insightful agenda filled with updates on the company’s progress and future plans.
Invitation to Attend
The invitation to the AGM includes all corresponding agenda items, ensuring that attendees are well-informed about the discussions that will take place. This open invitation highlights the company's dedication to involving its shareholders in key decisions.
Importance of Stakeholder Engagement
This AGM represents a vital opportunity for stakeholders to engage with Molecular Partners. The discussions will cover the innovative advancements and achievements in developing DARPin therapeutics, emphasizing the company’s ongoing mission to tackle medical challenges that existing drug modalities cannot readily address.
Financial Calendar Overview
In addition to the AGM, Molecular Partners has outlined important upcoming dates within its financial calendar:
- **April 16, 2025**: Annual General Meeting
- **May 15, 2025**: Interim Management Statement for Q1 2025
- **August 25, 2025**: Release of half-year results for 2025 (unaudited)
- **October 30, 2025**: Interim Management Statement for Q3 2025
Stay Updated
For the latest information on these events and others, stakeholders can visit the investor section of Molecular Partners' website. Transparency remains a cornerstone of the company’s ethos as it continues on its path of growth.
About Molecular Partners AG
Molecular Partners AG is engaged in the innovative design and development of DARPin therapeutics. As a clinical-stage biotech company, it aims to address unmet medical needs through its unique protein drugs. With a strong emphasis on oncology, Molecular Partners manages various programs in different stages of preclinical and clinical development. Founded in 2004, the company operates from its offices in Zurich and Concord, MA, USA, collaborating with leading pharmaceutical companies to maximize the impact of its therapies.
Contact Information
For additional details about Molecular Partners AG, you may reach out to:
- Seth Lewis, SVP Investor Relations & Strategy
Concord, Massachusetts, U.S.
Email: seth.lewis@molecularpartners.com
Tel: +1 781 420 2361 - Laura Jeanbart, PhD, Head of Portfolio Management & Communications
Zurich-Schlieren, Switzerland
Email: laura.jeanbart@molecularpartners.com
Tel: +41 44 575 19 35
Frequently Asked Questions
1. When is the Annual General Meeting for Molecular Partners?
The Annual General Meeting is scheduled for April 16, 2025.
2. Where will the AGM be held?
The AGM will take place at JED Events, Zürcherstrasse 39, 8952 Schlieren, Switzerland.
3. What will be discussed at the AGM?
The AGM will include discussions about the company's progress, future plans, and agenda items related to its DARPin therapeutic developments.
4. How can stakeholders stay informed about company events?
Stakeholders can visit the investor section of the Molecular Partners' website for up-to-date information on events and updates.
5. Who can be contacted for further information?
For further details, stakeholders can contact Seth Lewis or Laura Jeanbart through their respective emails provided above.
